In fact, it was observed that the SFX-01 treatment induced NRF2 expression in glioma cells; however, the NRF2 pathway was not completely activated, since the levels of antioxidant response enzymes regulated by NRF2, such as SOD1 and SOD2, were found unchanged after treatment, which was indicated by the persistence of elevated ROS levels [133]. This evidence concerns the gene NFE2L2 and central nervous system cancer.